Bcr-Abl(Bcr-Abl酪氨酸激酶)

Cat.No. 产品名称 Information

GC25669 Nilotinib hydrochloride Nilotinib hydrochloride (AMN-107) is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.

GC65592 SNIPER(ABL)-020

GC64462 Asciminib hydrochloride An allosteric inhibitor of Abl1

GC52104 Ponatinib (hydrochloride) An inhibitor of native and mutant Bcr-Abl

GC63332 S116836

GC62453 GZD856 formic

GC62207 Olverembatinib A Bcr/Abl inhibitor

GC62103 Vodobatinib Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively.

GC47771 NG 25 (hydrochloride hydrate) An inhibitor of MAP4K2 and TAK1

GC47452 Imatinib-d3 An internal standard for the quantification of imatinib

GC60930 Imatinib D4

GC60270 Nilotinib D6 An internal standard for the quantification of nilotinib

GC39612 Imatinib D8

GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib

GC45687 Dasatinib N-oxide A major metabolite of dasatinib

GC36807 ON 146040

GC36167 GMB-475 GMB-475 is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1 protein and recruit the E3 ligase Von Hippel-Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.

GC35897 DPH

GC35812 Dasatinib hydrochloride An inhibitor of Abl and Src

GC35753 CT-721

GC35682 CHMFL-ABL/KIT-155

GC35651 Cenisertib

GC35462 Bafetinib A Bcr-Abl inhibitor

GC43198 CAY10717 A multi-targeted kinase inhibitor

GC40080 Bosutinib-d8 An internal standard for the quantification of bosutinib

GC33368 BCR-ABL-IN-2

GC33351 CZC-8004 (CZC-00008004) A tyrosine kinase inhibitor

GC33343 BCR-ABL-IN-1

GC33201 GZD856

GC32867 Flumatinib (HHGV678) A Bcr-Abl inhibitor

GC32703 Asciminib (ABL001) An allosteric inhibitor of Abl1

GC11737 AG957 An inhibitor of Bcr-Abl and c-Abl

GC15314 PD 166326 An inhibitor of c-src and certain receptor tyrosine kinases, including c-abl

GC10607 GNF-7 A multi-kinase inhibitor

GC17294 CHMFL-ABL-053 CHMFL-ABL-053 (Compound 18a) 是一种有效的、选择性的、可口服的 BCR-ABL、SRC 和 p38 激酶抑制剂，对 ABL1、SRC 和 p38 的 IC50 值分别为 70、90 和 62 nM。

GC11140 Radotinib(IY-5511) A selective Bcr-Abl tyrosine kinase inhibitor

GC10314 Imatinib (STI571) 伊马替尼 (STI571) (STI571) 是一种口服生物可利用的酪氨酸激酶抑制剂，可选择性抑制 BCR/ABL、v-Abl、PDGFR 和 c-kit 激酶活性。伊马替尼 (STI571) (STI571) 通过在 ATP 结合位点附近结合而起作用，将其锁定在封闭或自我抑制的构象中，从而半竞争性地抑制蛋白质的酶活性。伊马替尼 (STI571) 也是 SARS-CoV 和 MERS-CoV 的抑制剂。

GC14007 DCC-2036 (Rebastinib) An orally bioavailable tyrosine kinase inhibitor

GC10915 GZD824 A Bcr/Abl inhibitor

GC13592 PD173955 A tyrosine kinase inhibitor

GC13914 Flumatinib mesylate A Bcr-Abl inhibitor

GC12779 PPY A PPY A 是一种有效的 T315I 突变体和野生型 Abl 激酶抑制剂，IC50 分别为 9 和 20 nM。 PPY A 抑制用野生型 Abl 和 Abl T315I 突变体转化的 Ba⁄F3 细胞，IC50 分别为 390 和 180 nM。 PPY A可用于慢性粒细胞白血病（CML）的研究。

GC12637 PD 180970 An inhibitor of Bcr-Abl

GC12172 1-Naphthyl PP1 Inhibitor of modified ‘analog-sensitive’ kinases

GC15079 GNF 5 An allosteric inhibitor of Bcr-Abl

GC10858 GNF 2 An allosteric inhibitor of Bcr-Abl

GC15579 Adaphostin Adaphostin (NSC 680410) 是 AG957 的金刚烷基酯，是一种有效的 p210bcr/abl 抑制剂 (IC50=14 μM)。 Adaphostin 在人 T 淋巴细胞白血病细胞系中诱导细胞凋亡（IC50 范围为 17 至 216 nM）。 Adaphostin 对慢性和急性髓性白血病细胞具有显着的选择性活性。 Adaphostin 增加了 CLL B 细胞内的活性氧 (ROS) 水平。

GC14075 Nocodazole A microtubule altering agent

GC10970 WP1130 A deubiquitinase inhibitor

GC14396 Ponatinib (AP24534) An inhibitor of native and mutant Bcr-Abl